Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
Psyence Biomedical Ltd. - Ordinary Shares (PBM)
Company Research
Source: GlobeNewswire
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that its Board of Directors (the “Board”) has approved its 2026 Financial Strategy and Capital Management Framework, which includes the authorization of a share repurchase program that the management may undertake in value generation conditions. The Board’s decision followed a thorough and strategic review of the Company’s financial position, capital structure, prevailing market conditions, and Nasdaq listing considerations. The Strategy is intended to protect shareholder value, and preserve capital to fund planned clinical and regulatory milestones. The Board believes the underlying value of the Company may not be reflected in the current market price of its common shares (“Common Shares”). As a result, depending upon future pric
Show less
Read more
Impact Snapshot
Event Time:
PBM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBM alerts
High impacting Psyence Biomedical Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PBM
News
- Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock SplitGlobeNewswire
- Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash [Canadian Business Journal (Canada)]Canadian Business Journal
- Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m CashGlobeNewswire
- Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial [Canadian Business Journal (Canada)]Canadian Business Journal
PBM
Sec Filings
- 1/14/26 - Form 6-K
- 1/13/26 - Form SCHEDULE
- 1/13/26 - Form 6-K
- PBM's page on the SEC website